Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations

被引:42
作者
Schleyer, E
Pursche, S
Köhne, CH
Schuler, U
Renner, U
Gschaidmeier, H
Freiberg-Richter, J
Leopold, T
Jenke, A
Bonin, M
Bergemann, T
le Coutre, P
Gruner, M
Bornhäuser, M
Ottmann, OG
Ehninger, G
机构
[1] Tech Univ Dresden, Med Klin & Poliklin 1, D-01307 Dresden, Germany
[2] Humboldt Univ, Med Klin Hamatol & Onkol, Berlin, Germany
[3] Goethe Univ Frankfurt, Med Klin 3, Frankfurt, Germany
[4] Tech Univ Dresden, Inst Organ Chem, D-8027 Dresden, Germany
[5] Novartis Pharma AG, Nurnberg, Germany
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2004年 / 799卷 / 01期
关键词
STI-571; N-desmethyl-STI;
D O I
10.1016/j.jchromb.2003.10.025
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An isocratic online-enrichment HPLC-assay was developed allowing for the simple and fast separation and quantitation of STI-571 and its main metabolite N-desmethyl-STI (N-DeSM-STI) in plasma, urine, cerebrospinal fluid (CSF), culture media and cell preparations in various concentrations using UV-detection at 260 nm. The analytical procedure consists of an online concentration of STI-571 and N-DesM-STI in the HPLC system followed by the elution on a ZirChrom-PBD analytical column. Time of analysis is 40 min including the enrichment time of 5 min. The detection limit is 10 ng/ml in plasma, CSF, culture medium (RPMI) and 25 ng/ml in urine for both STI-571 and N-DesM-STI. The intra-day precision, as expressed by the coefficient of variation (CV), in plasma samples ranges between 1.74 and 8.60% for STI-571 and 1.45 and 8.87% for N-DesM-STI. The corresponding values for urine measurements are 2.17-7.54% (STI-571) and 1.31-9.51% (N-DesM-STI). The inter-day precision analyzed over a 7-month time period was 8.31% (ST1-571) or 6.88% (N-DesM-STI) and 16.45% (STI-571) or 14.83% (N-DesM-STI) for a concentration of 1000 ng/ml in plasma and 750 ng/ml in urine, respectively. Moreover, we demonstrate that with an alternative. but more time and labor consuming sample preparation and the implementation of electrochemical detection, a detection limit < 10 ng/ml can be achieved. The method described was used to perform pharmacokinetic measurements of STI-571 and N-desmethyl-STI in patient samples and for kinetic measurements of intracellular STI-571 and N-DesM-STI following in vitro incubation. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:23 / 36
页数:14
相关论文
共 28 条
[1]   High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Lohne, J ;
Ramos, L ;
Khemani, L ;
Hayes, M ;
Tse, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :325-340
[2]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[3]  
Buchdunger E, 1996, CANCER RES, V56, P100
[4]  
Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
[5]  
DEININGER MW, 2003, J CLIN ONCOL, V8, P1
[6]   The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells [J].
Deininger, MWN ;
Goldman, JM ;
Lydon, N ;
Melo, JV .
BLOOD, 1997, 90 (09) :3691-3698
[7]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[8]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[9]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[10]  
FORD JM, 2002, IMATINIB MESILATE IN